Safe Harbor Statement

These presentations contain forward-looking statements (including, without limitation, information, and future guidance on the company's goals, the company's cell analysis business, priorities, revenue, revenue growth, growth opportunities, new products and solutions, customer service and innovation plans, financial condition and considerations, impact of acquisitions, the markets the company sells into, operations and manufacturing site plans) that involve risks and uncertainties that could cause results of Agilent to differ materially from management's current expectations. The words “anticipate,” “plan,” “estimate,” “expect,” “intend,” “will,” “should,” “forecast,” “project” and similar expressions, as they relate to the company, are intended to identify forward-looking statements.

In addition, other risks that the company faces in running its operations include the ability to execute successfully through business cycles; the ability to successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross margin pressures; the risk that our strategic and cost-cutting initiatives will impair our ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties on our markets and our ability to conduct business; the impact of currency exchange rates on our financial results; the ability to improve asset performance to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix, the adverse impacts of and risks posed by the COVID-19 pandemic, and other risks detailed in the company's filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the year ended Oct 31, 2021.

The company assumes no obligation to update the information in these presentations. These presentations and the Q&A that follows include non-GAAP measures. Non-GAAP measures exclude primarily the impacts of amortization of intangibles, acquisition and integration costs, transformational initiatives, and business exits and divestitures. We also exclude any tax benefits that are not directly related to ongoing operations and which are either isolated or are not expected to occur again with any regularity or predictability. With respect to the company's guidance, most of these excluded amounts pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy. Accordingly, no reconciliation to GAAP amounts has been provided.
Agilent’s “Build and Buy” Growth Strategy
Accelerate Our Momentum in Attractive Market Opportunities

Transform Analytical Lab

Gain Share Cancer Diagnostics & Genomics

Enter and Expand High Growth Markets

Strategic Enablers
- Innovation
- Digital
- M&A
- Geographic Penetration

One Agilent Culture
Why Cell Analysis…
Unique Opportunity to Address Important Market Challenges

Moving from a molecular basis of understanding disease to using the cellular ecosystem to target & treat disease

- The most debilitating, costly, and lethal 
  diseases are cell-related, mediated, or treated.
- Modeling the integrated activities comprised within a living cell is essential for disease research
- Advances in cell analysis and genome editing have created a revolution in cell engineering
- Cell, Gene & Immuno-therapies rapidly emerging as a pillar in therapeutics, driving an evolution of cell analysis tools
Traditional Techniques Evolving with Emerging Live-cell Capabilities

Scientists are using Immunology & the Immune System to Treat Cancer & Fight Infectious Disease

$5B^{(1)}$ Opportunity with Attractive Growth Drivers; 5-7%$^{(2)}$

- Emergence of promising new biologic therapeutic modalities
- Increased need for accelerated vaccine development to address evolving & persistent infectious diseases
- Need to understand the entire cellular ecosystem, in context of disease and immune response
- Simultaneous use of traditional platforms and live-cell, real-time techniques
- Coordinated workflows across multiple techniques

(1) and (2) based on internal company estimates
Our Journey
Enabling a Deeper Understanding Of The Cellular Environment

**Agilent** has a long history of innovation and leadership in providing tools for life science and chemical analysis across a variety of markets.

2000-2015
- **Agilent**

2015
- **Seahorse**
- **Seahorse Bioscience:** Live-cell metabolic analysis

2018
- **Luxcel**
- **Luxcel Bioscience:** Label-free sensor capabilities

2018
- **Acea**
- **Acea Biosciences:** Unique, real-time cell analysis and accessible, high-end flow cytometry

2019
- **BioTek**
- **BioTek Instruments:** Broad plate reader portfolio, imaging systems, and washer/dispenser technologies

BioTek C10 Confocal Imager
- **Cellular Imaging**

BioTek BioSpa
- **Cell Expansion**

Seahorse XF
- **Cell quality**

xCELLigence
- **Potency testing**

NovoCyte Quanteon
- **Immunophenotyping**

October 11, 2022
Strong Foundation Poised for Future Growth & Expansion

Differentiated Portfolio Targeted at Emerging High-growth Segments

FY2021

$375M+ Revenue

25% Core Growth

How We Win:

- Portfolio Breadth: combination of traditional techniques plus unique live-cell, kinetic measurement capabilities
- Accessibility: bringing advanced capabilities to bench-scientists & clinics (confocal microscopy & flow cytometry)
- Modular Workflows: integrating multiple techniques & applications – greater insights from the same samples
- Interoperability: enabling greater access to critical measurement tools with data consolidation & integration
Unique Portfolio Addressing Critical Customer Challenges
Maintaining Our Growth Momentum

Enabling Workflow Solutions Across Techniques, Platforms, and Applications

- Greater Insights – more information from same samples, across multiple platforms with integrated data analysis & reporting
- Workflow Expansion – combine unique live-cell capabilities with high-value traditional techniques targeted at emerging applications across the value-chain: discovery, development & production.

Geographic Coverage & Expansion
- Global portfolio coverage
- Deep scientific applications expertise
- Distribution harmonization

Global Service Capability Leverage
- Specialized service delivery & geographic expansion
- Leverage global service logistics and infrastructure

Unified Customer Engagement
- Unified digital engagement
- Cloud enablement